Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats

Experimental Physiology

Volumn 98, Issue 1, 2013, Pages 109-122

  Lo, Jennifer ^a   Patel, Vaibhav B ^a   Wang, Zuocheng ^a   Levasseur, Jody ^a   Kaufman, Susan ^a   Penninger, Josef M ^b   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXYNITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; HEART RATE; HYPERTENSION; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRESSOR RESPONSE; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 84872178401     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.067165     Document Type: Article

References (58)

1. Benter IF, Yousif MH, Anim JT, Cojocel C & Diz DI (2006). Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with l-NAME. Am J Physiol Heart Circ Physiol 290, H684-H691.
2. Bing OH, Conrad CH, Boluyt MO, Robinson KG & Brooks WW (2002). Studies of prevention, treatment and mechanisms of heart failure in the aging spontaneously hypertensive rat. Heart Fail Rev 7, 71-88.
3. Bodiga S, Zhong JC, Wang W, Basu R, Lo J, Liu GC, Guo D, Holland SM, Scholey JW, Penninger JM, Kassiri Z & Oudit GY (2011). Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunit. Cardiovasc Res 91, 151-161.
4. Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM & Conrad CH (1997). Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 96, 4002-4010.
5. Carretero OA & Oparil S (2000). Essential hypertension. Part I: definition and etiology. Circulation 101, 329-335.
6. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ & Wilcox CS (2002). Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39, 269-274.
7. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, Da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y & Penninger JM (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828.
8. de Gasparo M (2002). Angiotensin II and nitric oxide interaction. Heart Fail Rev 7, 347-358.
9. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ & Raizada MK (2006). ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91, 163-198.
10. Díez-Freire C, Vázquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, Torres R & Raizada MK (2006). ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 27, 12-19.
11. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL & Tang WH (2009). Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15, 565-571.
12. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS & Sen S (2008). Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52, 750-754.
13. Feng Y, Yue X, Xia H, Bindom SM, Hickman PJ, Filipeanu CM, Wu G & Lazartigues E (2008). Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res 102, 729-736.
14. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI & Gallagher PE (2005). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605-2610.
15. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RAS, Katovich MJ & Raizada MK (2011). Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96, 287-294.
16. Gill PS & Wilcox CS (2006). NADPH oxidases in the kidney. Antioxid Redox Signal 8, 1597-1607.
17. Gomes ER, Lara AA, Almeida PW, Guimarães D, Resende RR, Campagnole-Santos MJ, Bader M, Santos RA & Guatimosim S (2010). Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′, 5′-cyclic monophosphate-dependent pathway. Hypertension 55, 153-160.
18. Griendling KK & FitzGerald GA (2003). Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912-1916.
19. Griendling KK, Minieri CA, Ollerenshaw JD & Alexander RW (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74, 1141-1148.
20. Griendling KK, Sorescu D & Ushio-Fukai M (2000). NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86, 494-501.
21. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA & Raizada MK (2008). Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 51, 1312-1317.
22. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM & Raizada MK (2005). Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90, 783-790.
23. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C & Penninger JM (2005). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112-116.
24. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB & Ferrario CM (2004). Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43, 970-976.
25. Katovich MJ, Grobe JL, Huentelman M & Raizada MK (2005). Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. Exp Physiol 90, 299-305.
26. Kim S & Iwao H (2000). Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52, 11-34.
27. Koka V, Huang XR, Chung AC, Wang W, Truong LD & Lan HY (2008). Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 172, 1174-1183.
28. Lodi F, Cogolludo A, Duarte J, Moreno L, Coviello A, Peral De Bruno M, Vera R, Galisteo M, Jiménez R, Tamargo J & Perez-Vizcaino F (2006). Increased NADPH oxidase activity mediates spontaneous aortic tone in genetically hypertensive rats. Eur J Pharmacol 544, 97-103.
29. McKee PA, Castelli WP, McNamara PM & Kannel WB (1971). The natural history of congestive heart failure: the Framingham study. N Engl J Med 285, 1441-1446.
30. Masson R, Nicklin SA, Craig MA, McBride M, Gilday K, Gregorevic P, Allen JM, Chamberlain JS, Smith G, Graham D, Dominiczak AF, Napoli C & Baker AH (2009). Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2. Hypertension 53, 694-700.
31. Mehta PK & Griendling KK (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292, C82-C97.
32. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM & Reudelhuber TL (2008). Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103, 1319-1326.
33. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, Gross V, Hummel O, Maatz H, Patone G, Saar K, Vingron M, Weldon SM, Lindpaintner K, Hammock BD, Rohde K, Dietz R, Cook SA, Schunck WH, Luft FC & Hubner N (2008). Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40, 529-537.
34. Moretti JL, Burke SL, Davern PJ, Evans RG, Lambert GW & Head GA (2012). Renal sympathetic activation from long-term low-dose angiotensin II infusion in rabbits. J Hypertens 30, 551-560.
35. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM & Scholey JW (2006). Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 168, 1808-1820.
36. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z & Scholey JW (2010). Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59, 529-538.
37. Oudit GY & Penninger JM (2011). Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep 8, 176-183.
38. Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, Lo J, Grant MB, Zhong J, Kassiri Z & Oudit GY (2012a). Loss of Angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res 110, 1322-1335.
39. Patel VB, Bodiga S, Fan D, Das SK, Wang Z, Wang W, Basu R, Zhong J, Kassiri Z & Oudit GY (2012b). cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension 59, 1195-1203.
40. Raizada MK & Ferreira AJ (2007). ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50, 112-119.
41. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK & Harrison DG (1996). Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97, 1916-1923.
42. Sampaio WO, Henrique De Castro C, Santos RA, Schiffrin EL & Touyz RM (2007). Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50, 1093-1098.
43. Tallant EA, Ferrario CM & Gallagher PE (2005). Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289, H1560-H1566.
44. Tan Z, Wu J & Ma H (2011). Regulation of angiotensin-converting enzyme 2 and Mas receptor by Ang-(1-7) in heart and kidney of spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 12, 413-419.
45. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G & Turner AJ (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275, 33238-33243.
46. Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL, Tseng CD, Tseng YZ, Chiang FT & Lin JL (2008). Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 117, 344-355.
47. Varagic J, Ahmad S, Brosnihan KB, Groban L, Chappell MC, Tallant EA, Gallagher PE & Ferrario CM (2010). Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. Ther Adv Cardiovasc Dis 4, 17-25.
48. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A & Tummino P (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277, 14838-14843.
49. Wang W, Bodiga S, Das SK, Lo J, Patel V & Oudit GY (2012). Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev 17, 683-691.
50. Weber KT & Brilla CG (1991). Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83, 1849-1865.
51. Widdop RE, Sampey DB & Jarrott B (1999). Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. Hypertension 34, 964-968.
52. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Armitage ME, Ho H, Schmidt HH & Wingler K (2010). Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161, 885-898.
53. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM & Batlle D (2009). Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55, 90-98.
54. Yamazato M, Yamazato Y, Sun C, Diez-Freire C & Raizada MK (2007). Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49, 926-931.
55. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z & Oudit GY (2011a). Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57, 314-322.
56. Zhong JC, Basu R, Guo D, Chow FL, Byrns S, Shuster M, Loibner H, Wang X, Penninger JM, Kassiri Z & Oudit GY (2010). Angiotensin converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis and cardiac dysfunction. Circulation 122, 717-728.
57. Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, Gao PJ, Huang DY, Shuster M, Loibner H, Guo JM, Yu XY, Xiao BX, Gong ZH, Penninger JM & Oudit GY (2011b). Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept 166, 90-97.
58. Zile MR & Brutsaert DL (2002). New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105, 1503-1508.